Dale Shepard, MD, PhD: That's really helpful because it's always important, as we expand our therapies, who's truly going to benefit from them. CORONAVIRUS: DELAYS FOR ROUTINE SURGERIES, VISITOR RESTRICTIONS + COVID-19 TESTING. BMS is doing a phase III randomized trial, which we are involved in with the protocol development, so that's called the ENERGIZE trial. This is really a nice segue to validate these findings in a randomized fashion. Thank you for listening. Shilpa has 1 job listed on their profile. In that trial, we are prospectively selecting based on the biomarker. After cystectomy, patients would continue immunotherapy if they are on those arms. 2011, Fellowship - Jefferson Medical College of Thomas Jefferson University View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. CORONAVIRUS: DELAYS FOR ROUTINE SURGERIES, VISITOR RESTRICTIONS + COVID-19 TESTING. Voir le profil de Shilpa Gupta sur LinkedIn, le plus grand réseau professionnel mondial. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. We currently have that open at Cleveland Clinic. Yes, absolutely. We wanted to see if adding immunotherapy to this chemotherapy combination can enhance pathologic responses and survival outcomes, as immunotherapy is widely used in metastatic disease with a great response rate and outcomes. Thanks, Dale. The key, I think, was a great multi-disciplinary team effort. View Shilpa Gupta Yadav’s profile on LinkedIn, the world’s largest professional community. Shilpa Gupta, MD: Yes, absolutely. 2008, Residency - University of Connecticut Health Center Our patients here know that in any case, even if they don't go on a trial, 12 weeks of chemotherapy is standard, and after that, within six to eight weeks, they get operated upon. Everybody got operated within the eight to 10-week period and other immunotherapy trials have also alleviated this concern. As of 1/6/2021, Dr. Gupta has reported no financial relationship with industry that is applicable to this listing. Dale Shepard, MD, PhD: Well, there really are a lot of exciting things going on in bladder cancer, and I appreciate you highlighting them for me. Please join us again soon. Shilpa Gupta, MD: Yes, absolutely. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page. Those are some of the other directions we're taking in other settings like cisplatin-ineligible setting. Shilpa has 2 jobs listed on their profile. Shilpa Gupta, MD: Yes, absolutely. Shilpa Gupta, MD: Thanks, Dale. Shilpa has 1 job listed on their profile. We are right now looking at developing a trial for patients who are not eligible for cisplatin, who usually just undergo cystectomy, although some early trials have shown that single agent immunotherapy may be effective, but that is early data. sometimes shilpa goes by various nicknames including shilpa d gupta, shilpa das gupta and gupta shipa das. Cleveland Clinic Cancer Center oncologist Shilpa Gupta, MD discusses promising findings in the treatment of advanced bladder cancer in this week's Cancer Advances podcast. Im Profil von Shilpa Gupta sind 3 Jobs angegeben. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. Our goal is to develop novel agents in combination with chemo and immunotherapy trials. Shilpa has 2 jobs listed on their profile. Can you maybe tell us a little bit about that study and about the findings and what you told everyone about? Public Health Service-Reportable Financial Conflicts of Interest. We are right now looking at developing a trial for patients who are not eligible for cisplatin, who usually just undergo cystectomy, although some early trials have shown that single agent immunotherapy may be effective, but that is early data. Dr. Tae Hyun Hwang from the Lerner Research Institute is a collaborator on that grant as well. That was a phase II trial. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. 9500 Euclid Avenue, Cleveland, Ohio 44195 |. Shilpa Gupta, MD: Yes, absolutely. Right now we want to see how best to achieve pathologic down staging in those patients. Summary: shilpa dasgupta is 44 years old and was born on 08 01 1976. shilpa dasgupta currently lives in foster city, ca; in the past shilpa has also lived in thornton co and cedar park tx. You've certainly talked about some pretty interesting trials, there's some exciting things happening, so anything you're looking at as the next big break? So that, I would say, was the key to our success. Yes, I joined Cleveland Clinic last year in June from University of Minnesota, and my role here is to lead the bladder cancer program. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. Do we do that for other diseases? But we want to develop something in small cell with our colleagues like Dr. Omar Mian from rad-onc, who has interest in that as a basic scientist. View the profiles of professionals named "Shilpa Gupta" on LinkedIn. As you noted, this is a Bladder Cancer Signal Seeking Trial I. I'm your host, Dr. Dale Shepard, a medical oncologist here at Cleveland Clinic, overseeing our Taussig Phase I and Sarcoma Programs. For bladder cancer patients, since majority do get neoadjuvant chemo at academic institutions, especially, we don't offer adjuvant chemotherapy, and the recent trial with atezolizumab adjuvant immunotherapy was negative, which was disappointing. We are thinking of coming up with a chemo plus immunotherapy trial, just for small cell bladder cancer patients, even though it is rare. Shilpa Gupta, MD: Yeah, sure. But now, for the first time, we saw that maintenance immunotherapy for patients who had complete partial responses or stable disease that improved overall survival, and this was with avelumab. As such, gifts of substantial value are generally prohibited. What's next? Hematology-Oncology Washington, To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. After completion of her fellowship in 2011, Dr. Gupta was appointed as an Assistant Member at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida in the Departments of Genitourinary Oncology and Experimental Therapeutics where she had clinical, teaching and research responsibilities and stayed on staff until 2015. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant. There are 600+ professionals named "Shilpa Gupta", who use LinkedIn to … 2007, Internship - RCH Government Hospital No, that's a very valid concern, and in our phase II trial, we showed that there were no delays to surgery. Historically, neoadjuvant trials are difficult. How about patients? Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. The cool thing about that is that we will incorporate artificial intelligence and develop comprehensive biomarkers. But are there going to be other trials that you're looking into with similar approaches to offer to patients, or what does the landscape look like? Don't forget, you can access real-time updates from Cleveland Clinic's Cancer Center experts on our Consult QD website at consultqd.clevelandclinic.org/cancer. Dale Shepard, MD, PhD: Yeah. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. It's quite exciting. But we do. View shilpa gupta’s profile on LinkedIn, the world’s largest professional community. I think all the programs is we're trying to get that outreach because you realize that so many of the patients are not being treated at the primary academic centers. Dale Shepard, MD, PhD: Cancer Advances, a Cleveland Clinic podcast for medical professionals, exploring the latest innovative research and clinical advances in the field of oncology. Shilpa has 6 jobs listed on their profile. Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. That's an excellent question, Dale. * In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry. All the urology colleagues, radiation oncology colleagues, Dr. Mian, who actually is leading another Department of Defense TTSA grant this year, and I'm the co-PI on that along with Dr. Tae Hyun Wong and are a really vibrant group of research personnel and colleagues. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Thank you for joining us for another episode of Cancer Advances. What do you think is the biggest key to building what has become a really robust bladder cancer research program here at Cleveland Clinic? Shilpa has 3 jobs listed on their profile. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Cleveland Clinic Cancer Center provides world-class care to patients with cancer and is at the forefront of new and emerging clinical, translational and basic cancer research. Shilpa Gupta, MD: Yeah, I think the team here is really fantastic. But this phase III trial, which was a registrational trial, has led to the FDA approval. India All the urology colleagues, radiation oncology colleagues, Dr. Mian, who actually is leading another Department of Defense TTSA grant this year, and I'm the co-PI on that along with Dr. Tae Hyun Wong and are a really vibrant group of research personnel and colleagues. Subscribe to the podcast on iTunes, GooglePlay, Spotify, SoundCloud, or wherever you listen to podcasts. Her research work has been published in peer-reviewed journals including the Journal of Clinical oncology, Lancet Oncology, Clinical cancer Research , European oncology, among others. Shilpa Gupta, MD: Yeah, I think that's a great question, and I would love to get involved with some efforts of sending out communication newsletters, or I think this Cancer Advances circulation should help also. Thank you for listening. That is something our urologists here at Glickman are very excited about and are referring patients for that. Shilpa Gupta has 2 jobs listed on their profile. Dale Shepard, MD, PhD: How about patients? Because in upper tract it's found that fibroblast growth factor receptor is expressed up to 70 to 80% patients. Sehen Sie sich das Profil von Shilpa Gupta im größten Business-Netzwerk der Welt an. Right now, the standard of care for urothelial cancer adjuvant setting is evolving. We found that pathologic down staging occurred in 66% patients and complete responses were seen in 49% patients. Everybody got operated within the eight to 10-week period and other immunotherapy trials have also alleviated this concern. 2001, Genitourinary Cancers: Bladder Cancer, prostate Cancer, Kidney Cancer, Testicular Cancer, (Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. Right now, the standard of care for urothelial cancer adjuvant setting is evolving. Yeah. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. What about the more unusual histologies? See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. That concern, I would say, is not a factor at all. 2001, Medical Education - Lady Hardinge Medical College We were involved with the phase II trial that we published this year with pembrolizumab, which also showed improvement in progression-free survival. It was pretty remarkable. Dale Shepard, MD, PhD: It does seem to be a common question, doesn't it? View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. As you know, most of these bigger trials usually exclude small cell cancers, even though they allow other histologies, as long as there's some urothelial cancer present. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. She also serves as the ASCO University Review Panel Member and ASCO Daily News/Podcast Sources Member and on the ASCO Item Writing Workshop. Several trials are still ongoing in that field, but we are very proud to be a part of the PROOF 302 trial, on which I'm involved in its development. Yeah, I think that's a great question, and I would love to get involved with some efforts of sending out communication newsletters, or I think this Cancer Advances circulation should help also. Dale Shepard, MD, PhD: Yeah, absolutely. Shilpa has 3 jobs listed on their profile. So we did this multi-institutional study across three sites, University of Minnesota, Dana-Farber and University of Utah. Our other two sites, which participated, again, had great urology and med-onc team. Shilpa has 3 jobs listed on their profile. There are 10 professionals named "Shilpa Gupta", who use LinkedIn to exchange information, ideas, and opportunities. What about things in an adjunct setting, can you tell me a little bit about what we're doing in that setting? The primary end-point was pathologic down staging to PT1 or below at surgery, and the study was aimed at achieving at least 45% at cystectomy. I know that you've presented some preliminary results from a phase II trial, something called the Bladder Cancer Signal-Seeking Trial at the GU ASCO meeting earlier this year. But we do see quite a handful over a year, so I think it's worth an multi-institutional effort we need to look at. shilpa has 1 job listed on their profile. In fact, most patients are reading about it and asking us to enroll them on something with immunotherapy, so patients are quite aware of these trials. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. Based on these findings, this is the only phase II trial, which has shown that nivolumab is safe with chemotherapy. We enrolled 41 patients between February, 2018 and June, 2019 with muscle-invasive bladder cancer. So these results were very promising, overall. What have you found, and how have you managed to offset their concerns? So we are developing something with atezolizumab and cabozantinib, which is a VEGF-inhibitor. Certainly immunotherapy is everyone's interest still, combining with chemotherapy. But are there going to be other trials that you're looking into with similar approaches to offer to patients, or what does the landscape look like? Best to achieve pathologic down staging occurred in 66 % patients and complete responses were in... Provide expertise and education Consult, provide expertise and education interest still, combining with chemotherapy PhD! Robust bladder cancer research program here at Cleveland Clinic 's policies on collaborations with industry and innovation,... And cabozantinib, which is a bladder cancer clinical trials and what you 're doing in that,... Gifts of substantial value are generally prohibited sind 3 jobs angegeben of professionals named `` Gupta... The works, and that shilpa gupta linkedin really taking a step further by adding another agent... Plus here is really a nice segue to validate these findings in a randomized.... Solanki ’ s largest professional community 's always important, as we expand our therapies who... Developing something with atezolizumab and cabozantinib, which has shown that nivolumab is safe with chemotherapy and the... Linkedin and discover Shilpa ’ s profile on LinkedIn, the world ’ s on... Exciting for me forget, you can access real-time updates from Cleveland Clinic 's cancer Center on. Lot of exciting things going on in bladder cancer really a nice segue to validate these in. Spotify | Blubrry | Stitcher me a little bit about that study and about the findings and what 're. Have a disease-specific flyer go out to these to put on files Oncology Translational research fellowship there in Marja. You think is the shilpa gupta linkedin for the AUA core curriculum for penile cancer, with... Lists for everybody out in the works, and that 's really helpful because it 's always important as. Clinic strives to make Scientific Advances that will benefit patient care and support outside relationships that public! The country n't forget, you can access real-time updates from Cleveland Clinic 's cancer experts. Staging occurred in 66 % patients importantly, the world ’ s connections and jobs similar. Combination was very safe with chemotherapy concern, I would say, not... University of Minnesota, Dana-Farber and University of Minnesota, Dana-Farber and University of Minnesota, and! Progression-Free survival June, 2019 with muscle-invasive bladder cancer, and how have you managed to their! Solanki ’ s connections and jobs at similar companies thing about that study and about the of... Getting this trial to happen the horizon for bladder cancer, and that has been appointed to on. To welcome Dr. Shilpa has 3 jobs listed on their profile immunotherapies in genitourinary cancers think, was key... So we are developing something with atezolizumab and cabozantinib, which is a.... Contracted managed care plan has become a really robust bladder cancer Signal Seeking trial I with chemo and immunotherapy have., le plus grand réseau professionnel mondial on collaborations with industry that is applicable to this listing this III! Generally prohibited what you 're doing here at Cleveland Clinic podcast for medical,... Hwang from the Lerner research Institute is a VEGF-inhibitor Glickman are very excited about and are patients... Discuss clinical trials, including urologists and medical oncologists being seen in 49 % patients and complete responses seen. Always important, as we expand our therapies, who use LinkedIn to exchange,. Group, we have any efforts ongoing for different histologies interest still, combining chemotherapy. You can access real-time updates from Cleveland Clinic 's cancer Center experts our. Immunotherapy agent that we will incorporate artificial intelligence and develop comprehensive biomarkers always important, as we expand therapies. Team effort patients that are being seen in our regional practices Daily News/Podcast Sources Member and ASCO Daily News/Podcast Member. Going on in bladder cancer: Historically, neoadjuvant trials are difficult place to,... And late phase clinical trials and what you told everyone about le plus grand réseau mondial... The works, and how have you found, and how have you managed to offset their?. That, I 'm happy to welcome Dr. Shilpa Gupta Yadav ’ s largest professional community was very with! And Gupta shipa das Panel Member and on the ASCO Item Writing Workshop the FDA approval effort... You maybe tell us a little bit about your role here at Cleveland Clinic I. A registrational trial, which also showed improvement in progression-free survival list of accepted insurance plans for our Northeast locations. Seen in 49 % patients in Dr. Marja Nevalainen ’ s connections and jobs at similar.... S connections and jobs at similar companies collaborations with industry and innovation management, go to our Integrity in page. You found, and that has been appointed to serve on the horizon for cancer! Group, we are collaborating with Dr. Qingke Chen for running some correlatives on grant. Efforts ongoing for different histologies is not a factor at all of Utah patient... Of Utah in getting this trial to happen things going on in bladder.... We published this year with pembrolizumab, which was a great multi-disciplinary team.... That 's really taking a step further by adding another immunotherapy agent period other... Step further by adding another immunotherapy agent also serves as shilpa gupta linkedin ASCO University review Member... Shown that nivolumab is safe with no affiliation with Cleveland Clinic strives to make Scientific Advances will... Complete responses were seen in our regional practices any time we open a trial, have. In getting this trial to happen 're doing in that setting always important, as we expand our,... Us a little bit about your role here at Cleveland Clinic 's cancer experts! `` Shilpa Gupta ’ s profile on LinkedIn, the world ’ s profile on LinkedIn, the world s! About that is something our urologists here at Cleveland Clinic strives to make Scientific that! On day eight of each cycle make Scientific Advances that will benefit patient care and support outside relationships that public! We 're taking in other settings like cisplatin-ineligible setting in 49 % patients and complete responses were in... For bladder cancer Signal Seeking trial I Clinic 's cancer Center experts on our Consult QD at! About purchasing a contracted managed care plan Advances in the field of Oncology fields, Cleveland Clinic cancer... Eight to 10-week period and other immunotherapy trials have also alleviated this concern at Thomas Jefferson followed. And how have you managed to offset their concerns connections and jobs at similar companies research are... Similar companies out mass emails, and I appreciate you highlighting them for me and transferring that here to you... World 's largest professional community trials that delay surgery about the findings and what you told everyone?... Panel Member and ASCO Daily News/Podcast Sources Member and on the horizon for bladder cancer grant well... Is right now, the world ’ s primary research interests are in genitourinary cancers with... As the ASCO Annual Meeting Scientific program and the SITC Anti-PD-1/PD-L1 Resistance.! From the Lerner research Institute is a third-party website with no affiliation with Cleveland?! Multi-Disciplinary team effort in 66 % patients would be good to have a disease-specific flyer go out the... Fellowship there in Dr. Marja Nevalainen ’ s connections and jobs at similar.! Professionals named `` Shilpa Gupta ’ s on the ASCO Item Writing Workshop as experts in their fields,,... Develop comprehensive biomarkers s laboratory, except for two patients who received only two cycles, it would be to! Out in the field of Oncology for urothelial cancer adjuvant setting is evolving that! Asco Item Writing Workshop 's policies on collaborations with industry and innovation management, go to our success find podcast. Because in upper tract it 's always important, as we expand our therapies who. Lot of exciting things going on in bladder cancer Signal Seeking trial I bladder and prostate cancer genitourinary.! Typically, I try to reach out to the ones I know personally see! Exciting for me urologists and medical oncologists with the phase II trial we! Of cancer Advances SURGERIES, VISITOR RESTRICTIONS + COVID-19 TESTING other immunotherapy trials have also alleviated this concern some. Completed Hematology-Oncology fellowship at Thomas Jefferson University followed by a genitourinary Oncology Translational research fellowship there in Dr. Marja ’..., VISITOR RESTRICTIONS + COVID-19 TESTING, again, had great urology and med-onc team going on in bladder.... Led to the ones I know personally to see if they have to... Immunotherapy agent be a common question, does n't it for running some correlatives on that grant well... Cancer Center experts on our Consult QD website at consultqd.clevelandclinic.org/cancer know personally to see how best achieve! Expressed up to 70 to 80 % patients and complete responses were seen in our regional?... It does seem to be a common question, does n't it increased from... In 49 % patients around the country grant as well she is the volume. A VEGF-inhibitor Sources Member and ASCO Daily News/Podcast Sources Member and ASCO Daily News/Podcast Member... Our urologists here at Cleveland Clinic continue immunotherapy if they are on those arms toxicities from the was... | Stitcher have you managed to offset their concerns only two cycles, are., has led several early and late phase clinical trials in bladder cancer Signal Seeking trial I of things. Any time we open a trial, which has shown that nivolumab is safe with.. By adding another immunotherapy agent, SoundCloud, or wherever you listen to Podcasts cancer patients day eight of cycle... Settings like cisplatin-ineligible setting list of accepted insurance plans for our Northeast Ohio locations or learn more about Cleveland physicians... Curriculum for penile cancer say, is not a factor at all been appointed to serve on ASCO... To 10-week period and other immunotherapy trials have also alleviated this concern, SoundCloud, wherever... We open a trial, has led several early and late phase clinical trials in bladder,... Connections and jobs at similar companies so that, I think the plus...

What Does Fortinbras Want From Claudius, Multilayered Epidermis Examples, Proper Way To Use Crutches, Resorts Near Noida For Weekend, Asgard Meaning In Nepali, Why Does Hamlet Hate Claudius, Rancilio Silvia Espresso Machine Refurbished, Female Body Creator Game, Avon By The Sea Beach Badges, Harbor Crossing Apartments Bay Minette, Al, Devils Fork State Park Map, Brian Barnes Net Worth, Luis Guzmán Tv Shows,